دورية أكاديمية
Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study
| العنوان: | Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study |
|---|---|
| المؤلفون: | Falchero, Lionel, Guisier, Florian, Darrason, Marie, Boyer, Arnaud, Dayen, Charles, Cousin, Sophie, Merle, Patrick, Lamy, Régine, Madroszyk, Anne Catherine, Otto, Josiane, Tomasini, Pascale, Assoun, Sandra, Canellas, Anthony, Gervais, Radj, Hureaux, José, Le Treut, Jacques, Leleu, Olivier, Naltet, Charles, Tiercin, Marie, van Hulst, Sylvie, Missy, Pascale, Morin, Franck, Westeel, Virginie, Girard, Nicolas |
| المساهمون: | Laboratoire d'Informatique, du Traitement de l'Information et des Systèmes (LITIS), Université Le Havre Normandie (ULH), Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA), Centre Hospitalier Lyon Sud CHU - HCL (CHLS), Hospices Civils de Lyon (HCL), Hôpital Saint-Joseph Marseille, Clinique de l'Europe Amiens, Institut Bergonié Bordeaux, UNICANCER, CHU Gabriel Montpied Clermont-Ferrand, CHU Clermont-Ferrand, Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne (UCA), Institut Paoli-Calmettes (IPC), Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre de Lutte contre le Cancer Antoine Lacassagne Nice (UNICANCER/CAL), UNICANCER-Université Côte d'Azur (UniCA), Hôpital Nord CHU - APHM, AP-HP - Hôpital Bichat - Claude Bernard Paris, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), INSERM U64 AP-HP Hôpital Tenon, Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Tenon AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Régional de Lutte contre le Cancer François Baclesse Caen (UNICANCER/CRLC), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Hôpital Européen Fondation Ambroise Paré - Marseille, Centre Hospitalier d'Abbeville, CH de Saint-Malo Broussais, Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Intergroupe Francophone de Cancérologie Thoracique Paris (IFCT), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Université de Versailles Saint-Quentin-en-Yvelines - UFR Sciences de la santé Simone Veil (UVSQ Santé), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Institut Curie Paris, Hoffmann-LaRoche |
| المصدر: | ISSN: 0169-5002 ; Lung Cancer ; https://hal.science/hal-04229547Test ; Lung Cancer, 2023, 185, ⟨10.1016/j.lungcan.2023.107379⟩. |
| بيانات النشر: | HAL CCSD Elsevier |
| سنة النشر: | 2023 |
| المجموعة: | Université de Versailles Saint-Quentin-en-Yvelines: HAL-UVSQ |
| مصطلحات موضوعية: | Chemotherapy, Immunotherapy, Small cell lung cancer, Targeted therapy, [SDV]Life Sciences [q-bio], [SDV.CAN]Life Sciences [q-bio]/Cancer |
| الوصف: | International audience ; Background: Small cell lung cancer (SCLC) has a tendency towards recurrence and limited survival. Standard-of-care in 1st-line is platinum-etoposide chemotherapy plus atezolizumab or durvalumab, based on landmark clinical trials. Methods: IFCT-1905 CLINATEZO is a nationwide, non-interventional, retrospective study of patients with extensive-SCLC receiving atezolizumab plus chemotherapy as part of French Early Access Program. Objectives were to analyse effectiveness, safety and subsequent treatments. Results: The population analyzed included 518 patients who received atezolizumab in 65 participating centers. There were 66.2% male, mean age was 65.7 years; 89.1% had a performance status (PS) 0/1 and 26.6% brain metastases. Almost all (95.9%) were smokers. Fifty-five (10.6%) received at least 1 previous treatment. Median number of atezolizumab injections was 7.0 (range [1.0–48.0]) for a median duration of 4.9 months (95% CI 4.5–5.1). Atezolizumab was continued beyond progression in 122 patients (23.6%) for a median duration of 1.9 months (95% CI: [1.4–2.3]). Best objective response was complete and partial in 19 (3.9%) and 378 (77.1%) patients. Stable disease was observed in 50 patients (10.2%). Median follow-up was 30.8 months (95% CI: [29.9–31.5]). Median overall survival (OS), 12-, 24-month OS rates were 11.3 months (95% CI: [10.1–12.4]), 46.7% (95% CI [42.3–50.9]) and 21.2% (95% CI [17.7–24.8]). Median real-world progression-free survival, 6-, 12-month rates were 5.2 months (95% CI [5.0–5.4]), 37.5% (95% CI [33.3–41.7]) and 15.2% (95% CI [12.2–18.6]). For patients with PS 0/1, median OS was 12.2 months (95% CI [11.0–13.5]). For patients with previous treatment, median OS was 14.9 months (95% CI [10.1–21.5]). Three-hundred-and-twenty-six patients (66.4%) received subsequent treatment and 27 (5.2%) were still under atezolizumab at date of last news. Conclusions: IFCT-1905 CLINATEZO shows reproductibility, in real-life, of IMpower-133 survival outcomes, possibly attributed to selection of ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | hal-04229547; https://hal.science/hal-04229547Test; https://hal.science/hal-04229547/documentTest; https://hal.science/hal-04229547/file/PIIS0169500223009170.pdfTest |
| DOI: | 10.1016/j.lungcan.2023.107379 |
| الإتاحة: | https://doi.org/10.1016/j.lungcan.2023.107379Test https://hal.science/hal-04229547Test https://hal.science/hal-04229547/documentTest https://hal.science/hal-04229547/file/PIIS0169500223009170.pdfTest |
| حقوق: | http://creativecommons.org/licenses/by-nc-ndTest/ ; info:eu-repo/semantics/OpenAccess |
| رقم الانضمام: | edsbas.83A02996 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.lungcan.2023.107379 |
|---|